Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.74 |
| ▸ | ATP1A1 | P05023 | 13/20 | 0.74 |
| ▸ | ATP1B1 | P05026 | 13/20 | 0.74 |
| ▸ | ATP1A3 | P13637 | 13/20 | 0.74 |
| ▸ | ATP1B2 | P14415 | 13/20 | 0.74 |
| ▸ | ATP1A2 | P50993 | 13/20 | 0.74 |
| ▸ | ATP1B3 | P54709 | 13/20 | 0.74 |
| ▸ | FXYD2 | P54710 | 13/20 | 0.74 |
| ▸ | ATP1A4 | Q13733 | 13/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | ATP12A | P54707 | 1/20 | 0.74 |
| ▸ | HBB | P68871 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26042802 | 1.00 | TP53 (0.74) | TP53SMN1; SMN2ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL21681745 | 1.00 | TP53 (0.74) | TP53SMN1; SMN2ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL21578398 | 1.00 | TP53 (0.74) | TP53SMN1; SMN2ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL1483332 | 1.00 | TP53 (0.74) | TP53SMN1; SMN2ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL12370059 | 1.00 | TP53 (0.74) | TP53SMN1; SMN2ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL12557040 | 0.90 | ATP1A1 (0.78) | TP53SMN1; SMN2ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL13762512 | 0.90 | ATP1A1 (0.69) | TP53SMN1; SMN2ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL17864012 | 0.88 | ATP1A1 (0.75) | TP53SMN1; SMN2ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL11648611 | 0.88 | TP53 (0.59) | TP53SMN1; SMN2ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL15354321 | 0.88 | SMN1; SMN2 (0.68) | TP53SMN1; SMN2ATP1A1ATP1B1ATP1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110076278-A1 | Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders | BIONAUT PHARMACEUTICALS INC | 2011-03-31 | — | — | US | claimed |
| EP-1928470-A2 | MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES FOR THE TREATMENT OF OCULAR DISORDERS | Bionaut Pharmaceuticals (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007016656-A2 | MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES FOR THE TREATMENT OF OCULAR DISORDERS | BTG INTERNATIONAL LIMITED (GB) | 2007-02-08 | — | — | WO | claimed |
| EP-0684256-B1 | Improved process for the preparation of 3 beta, 14 beta-dihydroxyethialnaldehyde | SIGMA TAU IND FARMACEUTI (IT) | 1998-05-13 | — | — | EP | claimed |
| US-5596110-A | Process for the preparation of 3 β, 14 β-dihydroxyethianaldehyde | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1997-01-21 | — | — | US | claimed |
| EP-0684256-A2 | Improved process for the preparation of 3 beta, 14 beta-dihydroxyethialnaldehyde | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1995-11-29 | — | — | EP | claimed |
| US-20110076278-A1 | Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders | BIONAUT PHARMACEUTICALS INC | 2011-03-31 | — | — | US | disclosed |
| EP-1928470-A2 | MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES FOR THE TREATMENT OF OCULAR DISORDERS | Bionaut Pharmaceuticals (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007016656-A2 | MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES FOR THE TREATMENT OF OCULAR DISORDERS | BTG INTERNATIONAL LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| EP-0684256-B1 | Improved process for the preparation of 3 beta, 14 beta-dihydroxyethialnaldehyde | SIGMA TAU IND FARMACEUTI (IT) | 1998-05-13 | — | — | EP | disclosed |
| US-5596110-A | Process for the preparation of 3 β, 14 β-dihydroxyethianaldehyde | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1997-01-21 | — | — | US | disclosed |
| EP-0684256-A2 | Improved process for the preparation of 3 beta, 14 beta-dihydroxyethialnaldehyde | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1995-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076278-A1 | Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders | HIF1A, HIF1AN, HYOU1 | TP53 2477/4885SMN1; SMN2 3333/4885ATP1A1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.